Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.

By Á. Soriano, F. Marco, J. Martinez, E. Pisos, M. Almela, V. Dimova, D. Alamo, M. Ortega, J. López, J. Mensa. Clinical Infectious Diseases, 2008

809 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/e1dc69dc218540144a1306c82bf7f18451fc7e0a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Biochemistry

1. J. Dalovisio
2. W. Craig
3. M. Rybak
4. D. Levine
5. J. Rotschafer
6. M. Billeter
7. R. Moellering
8. B. Lomaestro

In Infectious Diseases

1. J. Dalovisio
2. W. Craig
3. M. Rybak
4. D. Levine
5. J. Rotschafer
6. M. Billeter
7. R. Moellering
8. B. Lomaestro

Citations in the corpus

• Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin (2008, background): “Data suggest that vancomycin has reduced activity against MRSA infections, with vancomycin MICs at the high end of the CLSI susceptibility range (6, 11, 16, 19, 20).”
• Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. (2019, background): “Soriano et al.(59) evaluated the influence of vancomycin MIC on outcome in a total of 414 episodes of MRSA bacteremic patients.”